NEOG stock news today

Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.

Form 8-K tells shareholders about important events such as deals, leadership changes or results.

Neogen gives FY2031 financial targets at investor event

Neogen laid out its long-term growth and margin plans at a 2026 investor day. The company set FY2031 goals for revenue expansion, adjusted gross margin and adjusted EBITDA margin.

Neogen posts stronger Q1 results, lifts FY27 sales guidance

Neogen reported first-quarter financial results that beat expectations. The company also raised its sales guidance for fiscal 2027.

Neogen holds Q1 2027 earnings call

Neogen discussed its first-quarter fiscal 2027 results during an earnings call. A full transcript of the call is available.

Neogen lifts FY2027 sales guidance to $885M-$890M

Neogen increased its fiscal 2027 sales forecast to a range of $885 million to $890 million, up from $880 million to $885 million. The new range compares with an analyst estimate of $883.175 million.

Neogen Q1 adjusted profit of $0.08 per share tops $(0.07) forecast; revenue $222.8M exceeds $208.175M view

Neogen's first-quarter adjusted earnings came in at $0.08 per share, ahead of the $(0.07) projection. The company's quarterly revenue of $222.8 million also surpassed the $208.175 million expectation.

Neogen, Hinalea Imaging team up on inspection technology

Neogen and Hinalea Imaging are working together to create imaging-based equipment for checking food quality and safety. The two firms will jointly develop these tools.

Guggenheim keeps Buy rating on Neogen, lifts target to $14

Guggenheim reiterated its Buy rating on Neogen and raised its price target to $14. The update reflects the firm's latest view on the stock.

FDA warns Neogen over contaminated HYCOAT linked to horse deaths

The FDA sent Neogen a warning letter about contamination in HYCOAT, a product intended to be sterile. The agency said its probe tied the contamination to the most horse fatalities ever seen from a flaw in an FDA-supervised veterinary medical item.

Piper Sandler raises Neogen to Overweight, price target to $14

Piper Sandler upgraded Neogen to Overweight from its prior rating and lifted its price target to $14. The change reflects the firm's updated view on the stock.

What is the latest news on NEOG?

Nov 3, 2026: Neogen Corp filed an insider trading report (Form 4) (SEC) · Oct 26, 2026: Neogen Corp filed an amended version of a report on a major company event (Form 8-K) (SEC) · Oct 8, 2026: Neogen gives FY2031 financial targets at investor event (Benzinga)

What has NEOG filed with the SEC recently?

Nov 3, 2026: Neogen Corp filed an insider trading report (Form 4) · Oct 26, 2026: Neogen Corp filed an amended version of a report on a major company event (Form 8-K)